Osteosarcoma of the limbs. Report of the EORTC-SIOP 03 trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation
✍ Scribed by J. M. V. Burgers; M. Van Glabbeke; A. Busson; P. Cohen; A. R. Mazabraud; J. S. Abbatucci; C. Kalifa; M. Tubiana; J. S. Lemerle; P. A. Voǔte; A. Van Oosterom; A. Pons; Th. Wagener; B. Van Der Werf-Messing; R. Somers; N. Duez
- Publisher
- John Wiley and Sons
- Year
- 1988
- Tongue
- English
- Weight
- 732 KB
- Volume
- 61
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
The European Organization for Research on Treatment of Cancer (EORTC) trial 20781, concerning osteosarcoma of the limbs is reported. After definitive treatment of the primary tumor with amputation or irradiation, adjuvant treatment was given, randomized into either 9 months of chemotherapy according to a modified Rosen schedule, or elective bilateral lung irradiation of 20 Gy, or 3 months of chemotherapy followed by lung irradiation. The 4-year disease-free survival and total survival were 24% and 4390, respectively, with no difference between the treatment arms. In the radiotherapy arms the lung metastases were more frequently suitable for surgical treatment. The survival of patients with either tibia localizations or higher age was somewhat better. Local recurrences occurred in 16% of patients, 50% of them with distant metastases. The trial was executed from 1978 to 1983; 205 patients were evaluable and eligible, and three toxic deaths occurred in the chemotherapy arms. Elective lung irradiation provided the same survival as the adjuvant chemotherapy given in that time.
Cancer 61 : 1024-1 03 1.1988.
STEOSARCOMA is a rare disease with an incidence 0 of 0.5 per lo5 persons per year, mainly in adolescent children. Many studies have been performed to try and improve the poor survival, or alternatively to spare the young patient an amputation which would not con-tribute to his or her ultimate cure.'-' The study to be reported here is a successor to the 0 2 osteosarcoma study of the European Organization for Research on Treatment of Cancer (EORTC) radiotherapy-chemotherapy group. conducted from 1970 to 1975 and re-From the